• TRM (USD/COP)COP 3,461.92 +1.37% +COP 46.82Colombia's official exchange rate (Financial Superintendence), valid Nov 21 to Nov 23
  • EuroCOP 3,804.64 +1.37% +COP 51.45Reference: TRM crossed with the European Central Bank rate of Nov 20; not the market quote
  • Mexican pesoCOP 181.56 +1.37% +COP 2.45Reference: TRM crossed with the European Central Bank rate of Nov 20; not the market quote

Q/C Technologies amends terms of its Series G and H preferred shares and warrants with PharmaCyte

FinanceInternationalTradingViewAI summary
Image: TradingView

Q/C Technologies amended the terms governing its Series G and H preferred shares and certain warrants through an agreement with PharmaCyte Biotech, which holds the majority of the preferred shares of both series. The changes revise amendment procedures and beneficial ownership limits. Separately, PharmaCyte consented to extend the maturity of the Series H preferred shares from March 2, 2027 to September 2, 2027. The transaction was disclosed to the SEC in a Form 8-K on November 20, 2026.

In 35 seconds

  • Q/C Technologies and PharmaCyte agreed to amend the terms of the Series G and H preferred shares and certain warrants.
  • The agreement revises amendment procedures and beneficial ownership limits.
  • PharmaCyte consented to extend the Series H preferred maturity from March 2 to September 2, 2027.
Read the full story at TradingView

IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.

Comments

Be respectful. Comments reported by several people are hidden until a moderator reviews them.

You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.

    Keep reading